Katie Witkiewitz1, Henry R Kranzler2, Kevin A Hallgren3, Stephanie S O'Malley4, Daniel E Falk5, Raye Z Litten5, Deborah S Hasin6, Karl F Mann7, Raymond F Anton8. 1. Department of Psychology , University of New Mexico, Albuquerque, New Mexico. 2. Department of Psychiatry , University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Psychiatry and Behavioral Sciences , University of Washington, Seattle, Washington. 4. Yale School of Medicine , New Haven, Connecticut. 5. National Institute on Alcohol Abuse and Alcoholism , Bethesda, Maryland. 6. Department of Epidemiology , Columbia University, New York, New York. 7. Medical Faculty Mannheim , Central Institute of Mental Health, Heidelberg University, Mannheim, Germany. 8. Department of Psychiatry and Behavioral Sciences , Medical University of South Carolina, Charleston, South Carolina.
Abstract
BACKGROUND: Abstinence and no heavy drinking days are currently the only Food and Drug Administration-approved end points in clinical trials for alcohol use disorder (AUD). Many individuals who fail to meet these criteria may substantially reduce their drinking during treatment, and most individuals with AUD prefer drinking reduction goals. One- and two-level reductions in World Health Organization (WHO) drinking risk levels have been proposed as alternative end points that reflect reduced drinking and are associated with reductions in drinking consequences, improvements in mental health, and reduced risk of developing alcohol dependence. The current study examined the association between WHO drinking risk level reductions and improvements in physical health and quality of life in a sample of individuals with alcohol dependence. METHODS: Secondary data analysis of individuals with alcohol dependence (n = 1,142) enrolled in the longitudinal, prospective COMBINE study, a multi site randomized placebo-controlled clinical trial, examining the association between reductions in WHO drinking risk levels and change in blood pressure, liver enzyme levels, and self-reported quality of life following treatment for alcohol dependence. RESULTS: One- and two-level reductions in WHO drinking risk level during treatment were associated with significant reductions in systolic blood pressure (p < 0.001), improvements in liver enzyme levels (all p < 0.01), and significantly better quality of life (p < 0.001). CONCLUSIONS: One- and two-level reductions in WHO drinking risk levels predicted significant improvements in markers of physical health and quality of life, suggesting that the WHO drinking risk level reduction could be a meaningful surrogate marker of improvements in how a person "feels and functions" following treatment for alcohol dependence. The WHO drinking risk levels could be useful in medical practice for identifying drinking reduction targets that correspond with clinically significant improvements in health and quality of life.
RCT Entities:
BACKGROUND: Abstinence and no heavy drinking days are currently the only Food and Drug Administration-approved end points in clinical trials for alcohol use disorder (AUD). Many individuals who fail to meet these criteria may substantially reduce their drinking during treatment, and most individuals with AUD prefer drinking reduction goals. One- and two-level reductions in World Health Organization (WHO) drinking risk levels have been proposed as alternative end points that reflect reduced drinking and are associated with reductions in drinking consequences, improvements in mental health, and reduced risk of developing alcohol dependence. The current study examined the association between WHO drinking risk level reductions and improvements in physical health and quality of life in a sample of individuals with alcohol dependence. METHODS: Secondary data analysis of individuals with alcohol dependence (n = 1,142) enrolled in the longitudinal, prospective COMBINE study, a multi site randomized placebo-controlled clinical trial, examining the association between reductions in WHO drinking risk levels and change in blood pressure, liver enzyme levels, and self-reported quality of life following treatment for alcohol dependence. RESULTS: One- and two-level reductions in WHO drinking risk level during treatment were associated with significant reductions in systolic blood pressure (p < 0.001), improvements in liver enzyme levels (all p < 0.01), and significantly better quality of life (p < 0.001). CONCLUSIONS: One- and two-level reductions in WHO drinking risk levels predicted significant improvements in markers of physical health and quality of life, suggesting that the WHO drinking risk level reduction could be a meaningful surrogate marker of improvements in how a person "feels and functions" following treatment for alcohol dependence. The WHO drinking risk levels could be useful in medical practice for identifying drinking reduction targets that correspond with clinically significant improvements in health and quality of life.
Authors: Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Katie Witkiewitz; Kevin A Hallgren; Henry R Kranzler; Karl F Mann; Deborah S Hasin; Daniel E Falk; Raye Z Litten; Stephanie S O'Malley; Raymond F Anton Journal: Alcohol Clin Exp Res Date: 2016-12-26 Impact factor: 3.455
Authors: Angela M Wood; Stephen Kaptoge; Adam S Butterworth; Peter Willeit; Samantha Warnakula; Thomas Bolton; Ellie Paige; Dirk S Paul; Michael Sweeting; Stephen Burgess; Steven Bell; William Astle; David Stevens; Albert Koulman; Randi M Selmer; W M Monique Verschuren; Shinichi Sato; Inger Njølstad; Mark Woodward; Veikko Salomaa; Børge G Nordestgaard; Bu B Yeap; Astrid Fletcher; Olle Melander; Lewis H Kuller; Beverley Balkau; Michael Marmot; Wolfgang Koenig; Edoardo Casiglia; Cyrus Cooper; Volker Arndt; Oscar H Franco; Patrik Wennberg; John Gallacher; Agustín Gómez de la Cámara; Henry Völzke; Christina C Dahm; Caroline E Dale; Manuela M Bergmann; Carlos J Crespo; Yvonne T van der Schouw; Rudolf Kaaks; Leon A Simons; Pagona Lagiou; Josje D Schoufour; Jolanda M A Boer; Timothy J Key; Beatriz Rodriguez; Conchi Moreno-Iribas; Karina W Davidson; James O Taylor; Carlotta Sacerdote; Robert B Wallace; J Ramon Quiros; Rosario Tumino; Dan G Blazer; Allan Linneberg; Makoto Daimon; Salvatore Panico; Barbara Howard; Guri Skeie; Timo Strandberg; Elisabete Weiderpass; Paul J Nietert; Bruce M Psaty; Daan Kromhout; Elena Salamanca-Fernandez; Stefan Kiechl; Harlan M Krumholz; Sara Grioni; Domenico Palli; José M Huerta; Jackie Price; Johan Sundström; Larraitz Arriola; Hisatomi Arima; Ruth C Travis; Demosthenes B Panagiotakos; Anna Karakatsani; Antonia Trichopoulou; Tilman Kühn; Diederick E Grobbee; Elizabeth Barrett-Connor; Natasja van Schoor; Heiner Boeing; Kim Overvad; Jussi Kauhanen; Nick Wareham; Claudia Langenberg; Nita Forouhi; Maria Wennberg; Jean-Pierre Després; Mary Cushman; Jackie A Cooper; Carlos J Rodriguez; Masaru Sakurai; Jonathan E Shaw; Matthew Knuiman; Trudy Voortman; Christa Meisinger; Anne Tjønneland; Hermann Brenner; Luigi Palmieri; Jean Dallongeville; Eric J Brunner; Gerd Assmann; Maurizio Trevisan; Richard F Gillum; Ian Ford; Naveed Sattar; Mariana Lazo; Simon G Thompson; Pietro Ferrari; David A Leon; George Davey Smith; Richard Peto; Rod Jackson; Emily Banks; Emanuele Di Angelantonio; John Danesh Journal: Lancet Date: 2018-04-14 Impact factor: 202.731
Authors: Kevin D Shield; Gerrit Gmel; Tara Kehoe-Chan; Deborah A Dawson; Bridget F Grant; Jürgen Rehm Journal: PLoS One Date: 2013-01-02 Impact factor: 3.240
Authors: Brian D Kiluk; Lara A Ray; Justin Walthers; Michael Bernstein; Jeffery S Tonigan; Molly Magill Journal: Alcohol Clin Exp Res Date: 2019-09-30 Impact factor: 3.455
Authors: Katie Witkiewitz; Nick Heather; Daniel E Falk; Raye Z Litten; Deborah S Hasin; Henry R Kranzler; Karl F Mann; Stephanie S O'Malley; Raymond F Anton Journal: Addiction Date: 2020-03-10 Impact factor: 6.526
Authors: Justin Knox; Jennifer Scodes; Katie Witkiewitz; Henry R Kranzler; Karl Mann; Stephanie S O'Malley; Melanie Wall; Raymond Anton; Deborah S Hasin Journal: Alcohol Clin Exp Res Date: 2020-07-03 Impact factor: 3.455
Authors: Robert L Cook; Zhi Zhou; Maria Jose Miguez; Clery Quiros; Luis Espinoza; John E Lewis; Babette Brumback; Kendall Bryant Journal: Alcohol Clin Exp Res Date: 2019-07-10 Impact factor: 3.455
Authors: Federico E Vaca; James Dziura; Fuad Abujarad; Michael V Pantalon; Allen Hsiao; Craig A Field; Gail D'Onofrio Journal: Contemp Clin Trials Date: 2020-09-16 Impact factor: 2.226
Authors: Vanessa A Jimenez; Nicole A R Walter; Tatiana A Shnitko; Natali Newman; Kaya Diem; Lauren Vanderhooft; Hazel Hunt; Kathleen A Grant Journal: J Pharmacol Exp Ther Date: 2020-09-01 Impact factor: 4.030
Authors: Federico E Vaca; James Dziura; Fuad Abujarad; Michael V Pantalon; Allen Hsiao; Craig A Field; Gail D'Onofrio Journal: Contemp Clin Trials Date: 2020-08-07 Impact factor: 2.226